Payment overview · 2025
General Payments
$671.01
30 reported records · 13 companies
Healthcare provider profile · identity verified
William P Bartlow, MD
Allopathic & Osteopathic Physicians|Family Medicine · PENNSDALE, PA · NPI 1881690501
Verified facts
What the public records show
CMS Open Payments records show William P Bartlow, MD received $671.01 in general payments during 2025 across 30 reported records.
Tandem Diabetes Care, Inc. accounted for 16.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $111.51 | 16.6% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $100.38 | 15.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $97.67 | 14.6% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $88.79 | 13.2% | 3 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $64.45 | 9.6% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $39.62 | 5.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $39.51 | 5.9% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $37.94 | 5.7% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $25.17 | 3.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.78 | 2.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.51 | 2.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.00 | 2.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.68 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $671.01 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $111.51 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $97.67 | 5 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $88.79 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $67.32 | 3 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $64.45 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $50.57 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $39.62 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $39.51 | 2 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $37.94 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.06 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $25.17 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| VARIVAX Normalized: varivax |
Biological | Merck Sharp & Dohme LLC | $15.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 473 | 136 |
| Lisinopril | Lisinopril | 382 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 376 | 111 |
| Omeprazole | Omeprazole | 361 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 246 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 245 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 236 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 233 | 51 |
| Eliquis | Apixaban | 211 | 39 |
| Gabapentin | Gabapentin | 196 | 49 |
| Furosemide | Furosemide | 163 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 158 | 46 |
| Potassium Chloride | Potassium Chloride | 150 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 143 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 132 | 29 |
| Metformin Hcl | Metformin Hcl | 118 | 33 |
| Montelukast Sodium | Montelukast Sodium | 115 | 27 |
| Metformin Hcl Er | Metformin Hcl | 107 | 34 |
| Trazodone Hcl | Trazodone Hcl | 107 | 31 |
| Losartan Potassium | Losartan Potassium | 101 | 32 |
| Famotidine | Famotidine | 99 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 27 |
| Carvedilol | Carvedilol | 91 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 25 |
| Jardiance | Empagliflozin | 85 | 23 |
| Simvastatin | Simvastatin | 84 | 25 |
| Clonazepam | Clonazepam | 66 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | 13 |
| Xarelto | Rivaroxaban | 62 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | suppressed |
| Meloxicam | Meloxicam | 55 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | suppressed |
| Levetiracetam | Levetiracetam | 53 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 52 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 13 |
| Ozempic | Semaglutide | 51 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 49 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | suppressed |
| Pregabalin | Pregabalin | 48 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 46 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 45 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 43 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | suppressed |
| Finasteride | Finasteride | 40 | 11 |
| Spironolactone | Spironolactone | 40 | suppressed |
| Trulicity | Dulaglutide | 40 | 12 |
| Alendronate Sodium | Alendronate Sodium | 39 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | 16 |
| Clonidine Hcl | Clonidine Hcl | 37 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 37 | suppressed |
| Allopurinol | Allopurinol | 36 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 12 |
| Ibuprofen | Ibuprofen | 36 | 11 |
| Torsemide | Torsemide | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | 13 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 33 | 28 |
| Glimepiride | Glimepiride | 33 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Alprazolam | Alprazolam | 27 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | 11 |
| Olanzapine | Olanzapine | 25 | suppressed |
| Prednisone | Prednisone | 25 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $671.01 · 30 records | Tandem Diabetes Care, Inc. | BREZTRI, CAPLYTA, CRYSVITA, ENFLONSIA, EVENITY, FREESTYLE LIBRE 3, GARDASIL 9, M-M-R II, PROLIA, PROQUAD, QULIPTA, SUBLOCADE, The Cologuard Plus Collection Kit, UBRELVY, VARIVAX, VIVITROL, VOQUEZNA, VRAYLAR, Wegovy, t:slim X2 Insulin Pump with Control-IQ | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error